Eli Lilly Sues Vendors Over Tirzepatide Fraud

Eli Lilly has filed lawsuits against three medical spas and online vendors—Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine—for selling products that falsely claim to contain tirzepatide, the active ingredient in its weight-loss drug Zepbound. The lawsuits, which were filed in federal and state courts in Indiana, Texas, and Washington, allege false advertising and potentially dangerous consumer practices. Despite the U.S. FDA recently removing tirzepatide from its short supply list, Lilly emphasized that the legal actions were independent of that status. The company accused Pivotal Peptides of selling the drug without prescriptions and alleged that the products were misleadingly marketed. Lilly aims to protect consumer safety and has previously taken action against over two dozen similar vendors. The lawsuits seek to halt the sale of these imitation products and obtain financial reparations for damages.